A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection

Abstract Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is closely associated with various malignancies. Considering the complex life cycle of EBV, developing vaccines targeting key entry glycoproteins to elicit robust and durable adaptive immune responses may provide better...

書誌詳細
出版年:	Nature Communications
主要な著者:	Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Miao Xu, Xiao Zhang
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2024-06-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-024-49546-w

類似資料

Precision Nanovaccines for Potent Vaccination
著者:: Hong Liu, 等
出版事項: (2024-07-01)

In Situ Cocktail Nanovaccine for Cancer Immunotherapy
著者:: Mohan Liu, 等
出版事項: (2023-11-01)

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice
著者:: Xinyu Zhang, 等
出版事項: (2024-12-01)

Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses
著者:: Haiwen Chen, 等
出版事項: (2021-10-01)

Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes
著者:: Qian Wu, 等
出版事項: (2023-12-01)

Eliciting Dual-Niche Immunological Priming by Acupoint Delivery of Nanovaccines
著者:: Lu Wang, 等
出版事項: (2025-05-01)

Urgency and necessity of Epstein-Barr virus prophylactic vaccines
著者:: Ling Zhong, 等
出版事項: (2022-12-01)

A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus
著者:: Ling Zhong, 等
出版事項: (2022-11-01)

Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics
著者:: Yufei Wang, 等
出版事項: (2024-04-01)

mRNA Nanovaccine Against Mycobacterium tuberculosis Elicits Robust Immunity in Mice
著者:: Mr Bubacarr J. B Touray
出版事項: (2025-03-01)

Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases
著者:: Anirban Sengupta, 等
出版事項: (2022-03-01)

Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region
著者:: Junping Hong, 等
出版事項: (2021-11-01)

The delivery and transmembrane transport mechanism of SVCV nanovaccine
著者:: Han Zhang, 等
出版事項: (2025-12-01)

Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice
著者:: Wesam E. Gawad, 等
出版事項: (2025-02-01)

CpG-Based Nanovaccines for Cancer Immunotherapy
著者:: Chen W, 等
出版事項: (2021-08-01)

Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice
著者:: Gabriela M. Escalante, 等
出版事項: (2024-09-01)

Spike Glycoprotein-Mediated Entry of SARS Coronaviruses
著者:: Lin Wang, 等
出版事項: (2020-11-01)

Multiepitope Subunit Peptide-Based Nanovaccine against Porcine Circovirus Type 2 (PCV2) Elicited High Antibody Titers in Vaccinated Mice
著者:: Viet Tram Duong, 等
出版事項: (2023-02-01)

The Role of Orthobunyavirus Glycoprotein Gc in the Viral Life Cycle: From Viral Entry to Egress
著者:: Han Gao, 等
出版事項: (2025-01-01)

Emerging Cationic Nanovaccines
著者:: Ana Maria Carmona-Ribeiro, 等
出版事項: (2024-10-01)

Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy
著者:: Aixian Zheng, 等
出版事項: (2024-04-01)

GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus
著者:: Danying Chen, 等
出版事項: (2019-01-01)

Simultaneous induction of immunogenic cell death and PD-L1 downregulation by bufalin-based nanovaccines for potentiate HCC immunotherapy
著者:: Zhe Li, 等
出版事項: (2025-12-01)

Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
著者:: Chen Shi, 等
出版事項: (2023-09-01)

Immunoinformatics Approach to Design a Multi-Epitope Nanovaccine against <i>Leishmania</i> Parasite: Elicitation of Cellular Immune Responses
著者:: Maritsa Margaroni, 等
出版事項: (2023-01-01)

Addressing Nanovaccine Strategies for Tilapia
著者:: Kim D. Thompson, 等
出版事項: (2023-08-01)

The Application of Nanovaccines in Autoimmune Diseases
著者:: Tang Y, 等
出版事項: (2024-01-01)

Self-adjuvanting cancer nanovaccines
著者:: Zhiyun Liao, 等
出版事項: (2022-07-01)

Engineering customized nanovaccines for enhanced cancer immunotherapy
著者:: Jinyu Guo, 等
出版事項: (2024-06-01)

328 Preclinical analyses and proof of concept clinical study of Epstein Barr Virus (EBV) specific genetically modified T cells against EBV associated malignancies
著者:: Ling Li, 等
出版事項: (2023-11-01)

The secret life of viral entry glycoproteins: moonlighting in immune evasion.
著者:: Jonathan D Cook, 等
出版事項: (2013-01-01)

Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response
著者:: Yingying Song, 等
出版事項: (2024-06-01)

A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models
著者:: Lei Zhang, 等
出版事項: (2025-03-01)

Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
著者:: Chen Shi, 等
出版事項: (2023-11-01)

High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma
著者:: Benjamin E. Warner, 等
出版事項: (2025-02-01)

An Immunomodulatory Zinc‐Alum/Ovalbumin Nanovaccine Boosts Cancer Metalloimmunotherapy Through Erythrocyte‐Assisted Cascade Immune Activation
著者:: Jing Zhao, 等
出版事項: (2024-02-01)

EBV gL-gH344-Ferritin Nanoparticle Vaccine Elicits Robust Immune Responses in Mice
著者:: Chenyu Li, 等
出版事項: (2025-05-01)

EBV-induced T-cell responses in EBV-specific and nonspecific cancers
著者:: Qiuting Zhang, 等
出版事項: (2023-09-01)

An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection
著者:: Dan Zhou, 等
出版事項: (2024-08-01)

Recent advances of nanovaccines on cancer theranostics
著者:: Xiaobing Yuan, 等
出版事項: (2025-02-01)